针对类似收费的受体:揭示了深静脉血栓瘤的潜在治疗策略
Wei Shao1,2, Zilong Wang1,2, Jian Wu1,2
1The First Clinical College, Gannan Medical University, Ganzhou, China.
Frontiers in immunology
|June 13, 2025
概括
收费类受体 (TLRs) 通过触发炎症,在深静脉血栓症 (DVT) 中发挥关键作用. 准这些受体可能为预防和治疗DVT提供新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 血管生物学 血管生物学
- 血栓形成研究研究
背景情况:
- 深静脉血栓症 (DVT) 是一种严重的血管疾病,涉及深静脉中的血栓,通常导致肺栓塞.
- 托尔类受体 (TLRs) 是先天免疫系统的一部分,越来越多地被认为是它们在DVT发展中的作用.
- TLRs识别分子模式,启动与血栓形成有关的炎症反应.
研究的目的:
- 审查目前关于TLRs在DVT病变发生中的作用的知识.
- 合成TLRs对DVT的贡献的分子机制.
- 探索针对TLR治疗DVT的治疗潜力.
主要方法:
- 对TLR和DVT研究的综合文献综述.
- 在DVT中涉及TLRs的分子机制的系统合成.
- 对针对TLR的潜在治疗策略的分析,包括抑制剂和对抗剂.
主要成果:
- TLRs涉及到关键的DVT过程,如血小板激活,内皮功能障碍和白细胞招募.
- 由TLRs启动的炎症级联与DVT中的血栓形成过程密切相关.
- 有证据表明,TLRs是DVT多因素病原发生的关键决定因素.
结论:
- TLRs是驱动DVT的炎症途径中的核心参与者.
- 针对TLRs为新的DVT预防和治疗策略提供了一个有希望的途径.
- 对TLR调制的进一步研究可能会导致对DVT的有效疗法.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Clot Retraction and Fibrinolysis
4.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K


